Galderma Group AG 2024 AR2
The report highlights Galderma's strong performance in 2024, delivering record net sales of 4.41 billion USD and surpassing 1 billion USD in Core EBITDA for the first time. It details the company's successful initial public offering on the SIX Swiss Exchange on March 22, 2024. The report outlines Galderma's progress on its ESG agenda, including achieving 100% renewable electricity across all four manufacturing plants and reducing water intensity by over 10% year-on-year. Additionally, it highlights the landmark U.S. FDA approvals for Nemluvio and the expansion of the global training network, GAIN, which engaged over 225,000 healthcare professionals.
Company: Galderma Group AG
Sector: Health Care
Country: Switzerland
Year: 2024
Type: AR2
Pages: 91
Galderma Group AG
Annual Report
The report highlights Galderma's strong performance in 2024, delivering record net sales of 4.41 billion USD and surpassing 1 billion USD in Core EBITDA for the first time. It details the company's successful initial public offering on the SIX Swiss Exchange on March 22, 2024. The report outlines Galderma's progress on its ESG agenda, including achieving 100% renewable electricity across all four manufacturing plants and reducing water intensity by over 10% year-on-year. Additionally, it highlights the landmark U.S. FDA approvals for Nemluvio and the expansion of the global training network, GAIN, which engaged over 225,000 healthcare professionals.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Renewable Energy
Women in Management
Employees